Analysts Expect Joint Corp (NASDAQ:JYNT) to Announce -$0.08 Earnings Per Share

Equities analysts predict that Joint Corp (NASDAQ:JYNT) will announce earnings of ($0.08) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Joint’s earnings, with the lowest EPS estimate coming in at ($0.10) and the highest estimate coming in at ($0.06). Joint posted earnings of $0.03 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 366.7%. The firm is expected to issue its next quarterly earnings report on Thursday, August 13th.

According to Zacks, analysts expect that Joint will report full year earnings of $0.04 per share for the current fiscal year, with EPS estimates ranging from $0.01 to $0.07. For the next year, analysts anticipate that the business will post earnings of $0.29 per share, with EPS estimates ranging from $0.26 to $0.32. Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Joint.

Joint (NASDAQ:JYNT) last posted its earnings results on Thursday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The firm had revenue of $13.64 million during the quarter, compared to the consensus estimate of $13.03 million. Joint had a net margin of 6.20% and a return on equity of 66.44%.

Several brokerages have recently weighed in on JYNT. Craig Hallum started coverage on shares of Joint in a research note on Thursday. They set a “buy” rating and a $24.00 price target for the company. Maxim Group reaffirmed a “buy” rating and set a $22.00 target price on shares of Joint in a report on Friday, May 8th. DA Davidson lifted their price objective on shares of Joint from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, June 11th. Zacks Investment Research lowered shares of Joint from a “hold” rating to a “sell” rating in a research report on Thursday, June 11th. Finally, TheStreet downgraded Joint from a “b-” rating to a “c+” rating in a research report on Friday, April 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $21.67.

NASDAQ:JYNT traded up $1.00 during trading hours on Wednesday, hitting $14.87. 1,512 shares of the stock were exchanged, compared to its average volume of 118,545. The company has a quick ratio of 1.15, a current ratio of 1.15 and a debt-to-equity ratio of 2.02. Joint has a twelve month low of $7.67 and a twelve month high of $21.80. The company has a market capitalization of $193.39 million, a P/E ratio of 67.59 and a beta of 1.16. The company’s 50 day moving average is $14.35 and its two-hundred day moving average is $14.29.

Institutional investors and hedge funds have recently modified their holdings of the stock. Marshall Wace North America L.P. bought a new position in Joint during the 1st quarter valued at about $47,000. California Public Employees Retirement System bought a new position in shares of Joint during the fourth quarter valued at approximately $369,000. Principal Financial Group Inc. purchased a new stake in shares of Joint in the fourth quarter worth approximately $174,000. State Street Corp lifted its stake in shares of Joint by 2.5% during the 4th quarter. State Street Corp now owns 252,138 shares of the company’s stock worth $4,070,000 after acquiring an additional 6,203 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in Joint by 4,641.7% during the 4th quarter. Bank of Montreal Can now owns 54,198 shares of the company’s stock valued at $875,000 after acquiring an additional 53,055 shares during the period. Institutional investors own 76.24% of the company’s stock.

About Joint

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.

Further Reading: Hedge Funds – How They Work For Investors

Get a free copy of the Zacks research report on Joint (JYNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.